SAN FRANCISCO -- Elan (ELN) said in a breakout session Tuesday at the J.P. Morgan Healthcare Conference that it is considering all options: strategic partners, selling off certain assets, a merger and an outright sale.The latter option seems a very remote possibility, mainly because Elan has well over $1 billion in debt coming due in 2011. That's not a nut potential suitors are going to want to take on right now. Take note, too, that if Elan is sold, Biogen Idec ( BIIB - Get Report), the company's Tysabri marketing partner, gets negotiating rights to wrest away full control of the drug. Elan shares have been strong this year, in part because of semi-persistent rumors that Pfizer ( PFE - Get Report) was interested in buying the company. After the last two days of meeting here, Elan management appears to have pretty much put that rumor to bed. I'm having breakfast with Elan management tomorrow, including CEO Kelly Martin, whom I named Worst Biotech CEO of 2008. Perhaps I should bring my own oatmeal?
TheStreet’s Fundamentals of Investing Course will teach you the keys to making the right decisions in any market.
TheStreet’s Personal Finance Essentials Course will teach you money management basics and investing strategies to help you avoid major financial pitfalls.
TheStreet Courses offers dedicated classes designed to improve your investing skills, stock market knowledge and money management capabilities.
More from Stocks
Stocks End Slightly Higher in Cautious Trading Ahead of Federal Reserve Meeting
Stocks end moderately ahead as investors are adopting a cautious stance heading into this week's Federal Reserve meeting.
Medical Marijuana Card: Everything You Need to Know
Trying to get a medical marijuana card? Here's what you need to know.
Apple's Reported 2020 iPhone Plans Are a Positive for Broadcom
According to a new report from a respected analyst, Apple plans to launch 5.4-inch and 6.7-inch flagship iPhones next year, each of which will feature quite a few Broadcom 5G RF chips.